Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637917 · ClinicalTrials.gov registry record
Pulse Oximetry Performance Comparison in Newborns
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 120
- Enrollment target
NCT06637917: Completed study, sponsored by Medtronic - MITG.
NCT06637917 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06637917 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The overall purpose is to directly compare pulse rate (PR) acquisition and oxygen saturation performance between two pulse oximeters (PO) in newborns.
Interventions
- DEVICE OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System
- DEVICE LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter
- DEVICE 1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2025-09-18 |
What the finished NCT06637917 record still lists
NCT06637917 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System is the first listed.
NCT06637917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06637917 about?
NCT06637917 is a clinical study titled "Pulse Oximetry Performance Comparison in Newborns". The overall purpose is to directly compare pulse rate (PR) acquisition and oxygen saturation performance between two pulse oximeters (PO) in newborns.
What is the current status of trial NCT06637917?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2024-09-10. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT06637917?
The interventions under investigation include: OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System (DEVICE), LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter (DEVICE), 1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor (DEVICE).
Who is sponsoring clinical trial NCT06637917?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI